Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Small molecule RNA therapeutics to target prostate cancer [DMS MaP-seq]

ABSTRACT: Small molecule RNA therapeutics to target prostate cancer [DMS MaP-seq]

PROVIDER: PRJNA1193668 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR31592112_1.fastq.gz	Fastqsanger.gz
	SRR31592112_2.fastq.gz	Fastqsanger.gz
	SRR31592113_1.fastq.gz	Fastqsanger.gz
	SRR31592113_2.fastq.gz	Fastqsanger.gz
	SRR31592114_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 64

Similar Datasets

Small molecule RNA therapeutics to target prostate cancer [DMS MaP-seq]

Project description:Tuning protein expression by targeting RNA structure using small molecules is an unexplored avenue for cancer treatment. To understand whether this vulnerability could be therapeutically targeted in the most lethal form of prostate cancer, castrate-resistant prostate cancer (CRPC), we used a clinical small molecule, zotatifin, that targets the RNA helicase and translation factor eIF4A. Zotatifin repressed tumorigenesis in patient-derived and xenograft models and prolonged survival in vivo alongside hormone therapy. Genome-wide transcriptome, translatome, and proteomic analysis revealed two important translational targets: Androgen Receptor (AR), a key oncogene in CRPC, and hypoxia-inducible factor 1A (HIF1A), an essential cancer modulator in hypoxia. We solved the structure of the 5’UTRs of these oncogenic mRNAs and strikingly observed complex structural remodeling of these select mRNAs by this small molecule. Remarkably, tumors treated with zotatifin become more sensitive to radiotherapy, usually blunted by HIF1A. Therefore, ‘translatome therapy’ opens new avenues to treat the deadliest cancers.

2025-02-16 | GSE283444 | GEO

Small molecule RNA therapeutics to target prostate cancer [Ribo-seq]

Project description:Small molecule RNA therapeutics to target prostate cancer [Ribo-seq]

| PRJNA1193670 | ENA

Small molecule RNA therapeutics to target prostate cancer [RNA-seq]

Project description:Small molecule RNA therapeutics to target prostate cancer [RNA-seq]

| PRJNA1193667 | ENA

Enhanced DMS-MaP enables superior RNA structural analysis

Project description:We develop an enhanced MaP protocol based on MarathonRT and bioinformatic optimizations which enables robust DMS probing of all four RNA nucleotides within living cells. We demonstrate this on RNA from E. coli and HEK293 cell lines.

2023-05-12 | GSE225383 | GEO

4U-DMS-MaP probing of nascent ribosomes

Project description:4U-DMS-MaP probing of nascent ribosomes

| PRJNA659772 | ENA

Enhanced DMS-MaP enables superior RNA structural analysis

Project description:Enhanced DMS-MaP enables superior RNA structural analysis

| PRJNA935379 | ENA

Small molecule RNA therapeutics to target prostate cancer [RNA-seq]

2025-02-16 | GSE283446 | GEO

Small molecule RNA therapeutics to target prostate cancer [Ribo-seq]

2025-02-16 | GSE283445 | GEO

Targeted DMS probing of SF3A3 5' UTR

Project description:To delineate the native structure of SF3A3 5'UTR, RNA was harvested from IMR90 human fibroblasts. Using specific primers and DMS-MaPSeq pipeline, we validated individual base pairing probabilities within the endogenous 5'UTR of SF3A3 (samples described as 'in vivo' transcribed). DMS-MaP-Seq is based on the principle that DMS is highly reactive to solvent-accessible, unpaired adenine (A) and cytosine (C) residues, but remains inert toward base-paired A and C engaged in Watson-Crick interactions (Rouskin et al., 2014). Using this methodology, we identify stable stem-loop structure (SL3) positioned within SF3A3 5'UTR. To further validate the functional importance of SL3, the structural point mutant (SF3A3 5'UTR mut: A55C and U95A) and rescue (SF3A3 5'UTR res: A55C and U95A and rescuing point mutations G61U and U100G) sequences of SF3A3 5'UTR were cloned into the reporter plasmid. For the validation of these mutate-and-rescue constructs, plasmids were in vitro transcribed and either used directly (samples described as 'in vitro') for DMS-MaP-Seq probing.

2021-03-25 | GSE147504 | GEO

DMS-MaPseq: A genome-wide or targeted approach for RNA structure probing in vivo

Project description:Here we present dimethyl sulfate mutational profiling with sequencing (DMS-MaPseq), which encodes DMS modifications as mismatches using a thermostable group II intron reverse transcriptase (TGIRT). DMS-MaPseq yields a high signal-to-noise ratio, can report multiple structural features for each molecule, and allows genome-wide studies as well as focused investigations of low abundance RNAs. We apply DMS-MaPseq to Drosophila melanogaster ovaries—the first experimental analysis of RNA structure in an animal tissue—and demonstrate its utility in the discovery of a functional RNA structure involved in the non-canonical GUG translation initiation of the human FXR2 mRNA. Additionally, we use DMS-MaPseq to compare the in vivo structure of messages in their pre-mRNA and mature forms. These applications illustrate DMS-MaPseq’s capacity to dramatically expand our ability to monitor RNA structure in vivo.

2016-09-16 | GSE84537 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data